Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14161366 | 0.87 | GSK3B (0.57) | GSK3BMEN1KMT2AMAPTGAA | |
| SCHEMBL1185712 | 0.85 | MAPT (0.49) | KMT2AMAPTGAAALDH1A1CYP2D6 | |
| SCHEMBL6746842 | 0.85 | VCAM1 (0.46) | GSK3BMAPTGAAALDH1A1CYP2D6 | |
| SCHEMBL5526148 | 0.83 | GSK3B (0.57) | GSK3BMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL101549 | 0.83 | CASP6 (0.46) | KMT2AMAPTGAAALDH1A1CYP2D6 | |
| SCHEMBL2156916 | 0.82 | CES1 (0.54) | MAPTGAAALDH1A1CYP2D6CASP6 | |
| SCHEMBL10948000 | 0.82 | VCAM1 (0.62) | MEN1KMT2AMAPTGAAALDH1A1 | |
| SCHEMBL2054452 | 0.82 | TSHR (0.66) | GSK3BMEN1KMT2AMAPTGAA | |
| SCHEMBL16132076 | 0.82 | GSK3B (0.56) | GSK3BMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL239392 | 0.82 | VCAM1 (0.68) | GSK3BMEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635578-B1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | HENGRUI USA LTD (US) | 2015-12-16 | — | — | EP | disclosed |
| US-8871767-B2 | 2-arylimidazo[1,2-B]pyridazine, 2-phenylimidazo[1,2-A]pyridine, and 2-phenylimidazo[1,2-A]pyrazine derivatives | HENGRUI (USA) LTD. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2635578-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | Hengrui (USA) Ltd. (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20120178751-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | HENGRUI (USA), LTD. | 2012-07-12 | — | — | US | disclosed |
| WO-2012088411-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | PAMLICO PHARMACEUTICAL INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20100056525-A1 | 5- AND 6- SUBSTITUTED BENZIMIDAZOLE THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| WO-2008070354-A2 | 5- AND 6- SUBSTITUTED BENZIMIDAZOLE THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| US-6696573-B1 | SYNTHESIS OF SUCH AS 2-(N-(2-(9H-CARBAZOL-2-YLOXY)ETHYL))-AMINO-1-((3 -METHYLSULFONYLAMINO)PHENYL)ETHANOL WITH ENHANCED OPTICAL PURITY | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2004-02-24 | — | — | US | disclosed |
| US-20030225289-A1 | Process for the preparation of tricyclic amino alcohol derivatives | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1209150-A1 | PROCESSES FOR THE PREPARATION OF TRICYCLIC AMINO ALCOHOL DERIVATIVES | Asahi Kasei Kabushiki Kaisha (JP) | 2002-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056525-A1 | 5- AND 6- SUBSTITUTED BENZIMIDAZOLE THIOPHENE COMPOUNDS | CYP3A5, CYP2B6, CYP3A4 | GSK3B 3491/4885MEN1 2388/4885KMT2A 3724/4885 |
| US-20030225289-A1 | Process for the preparation of tricyclic amino alcohol derivatives | ADH1A, ADH1C, OXER1 | GSK3B 4015/4885MEN1 3399/4885KMT2A 938/4885 |
| US-20120178751-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | PRXL2A, CDK2, CCNA2 | GSK3B 2482/4885MEN1 1837/4885KMT2A 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.